Avtor/Urednik		Šabovič, M
Naslov		Vloga rekombinantnih zdravil v zdravljenju kardiovaskularnih bolezni
Prevedeni naslov		The role of recombinant drugs in the treatment of cardiovascular diseases
Tip		članek
Vir		Farm Vestn
Vol. in št.		Letnik 47, št. Suppl
Leto izdaje		1996
Obseg		str. 157-62
Jezik		slo
Abstrakt		Recombinant gene technology has influenced the development of cardiovascular drugs. Recombinant tissue-type plasminogen activator (rt-PA) has already been approved for clinical use. Its main indications is fibrinolytic treatment of acute myocardial infarction. In comparison to streptokinase, which is the standard thrombolytic agent, rt-PA is slightly, but significantly, more effective. Unfortunately, it is also much more expensive. It is mainly used in the United States, whereas in Slovenia it is not licensed. In the United States and a few European coutries Abciximab (monoclonal antibodies againts platelet receptors GPIIb/IIIa) has been approved for the prevention of reocclusion after PTCA. Other recombinant fibrinolytic, antiplatelet and anticoagulant drugs are being tested in clinical trials. It seems likely that some of them will replace the existing antithrombotic drugs.
Deskriptorji		CARDIOVASCULAR DISEASES RECOMBINANT PROTEINS FIBRINOLYTIC AGENTS ALTEPLASE ANTICOAGULANTS